News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK's National Institute for Clinical Excellence (NICE) Nixes AstraZeneca PLC (AZN) Breast Cancer Drug



8/23/2011 7:12:08 AM

AstraZeneca PLC's (AZN) breast cancer drug Faslodex doesn't represent value for money and consequently shouldn't be made available on the U.K.'s publicly funded National Health Service, according to the country's medical cost-effectiveness body, the National Institute for Health and Clinical Excellence. NICE said its independent appraisal committee decided not to back Faslodex, also known as fulvestrant, as an alternative to aromatase inhibitor therapy in postmenopausal women who have locally advanced or metastatic breast cancer that is estrogen-receptor-positive.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES